Resmetirom introduced as a positive control in the CDAHFD model
SMC Laboratories has introduced Resmetirom, a THR-β agonist, as a positive control in the CDAHFD model for nonclinical MASH studies.
This addition enables clearer and more reproducible benchmarking of antifibrotic efficacy, further strengthening our nonclinical evaluation platform for MASH and related liver diseases.
